Could a platelet booster help kids with bone marrow failure?

NCT ID NCT07001254

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding romiplostim, a drug that stimulates platelet production, to standard immunosuppressive therapy can improve blood cell counts in children and young adults with severe aplastic anemia. The study will enroll 15 participants aged 2 to 21 who are either newly diagnosed or have not responded to prior treatments. The main goal is to see if more patients achieve normal blood counts without needing transfusions by 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Romiplostim (a drug that boosts platelet production) plus standard immunosuppressive therapy
What this could lead to
If it works, this could offer a new treatment option for children and young adults with severe aplastic anemia, potentially improving blood cell counts and reducing the need for transfusions.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Iowa Health Care

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.